FGP
ABUS icon

Freestone Grove Partners’s Arbutus Biopharma ABUS Stock Holding History

Freestone Grove Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,006
Closed -$81K – 994
2026
Q1 		$81K Buy
+18,006
New +$78.7K ﹤0.01% 817

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Freestone Grove Partners's ABUS Position: Q2 2026 in Review

Freestone Grove Partners sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 18,006 shares — an estimated $81K sold.

Freestone Grove Partners first reported a position in ABUS in Q1 2026 and held it in 1 quarter. The position peaked at $81K in Q1 2026. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Freestone Grove Partners reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 18,006 Arbutus Biopharma shares in Q2 2026, an estimated $81K.
  • Freestone Grove Partners first reported a position in Arbutus Biopharma in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Arbutus Biopharma position peaked at $81K in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.